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Epstein–Barr virus (EBV) infects and transforms resting B lymphocytes in vitro. The virus can also cause B cell lymphomas in
immunosuppressed humans. Indeed, EBV-mediated post-transplant lymphoproliferative disease causes significant complications in transplant
recipients, including loss of the transplanted organ and even death. The limited treatment options include, nonspecific targeting of B cell surface
antigens with monoclonal antibodies or withdrawal of immunosuppression. These therapies fail in ∼50% of patients. Clearly, treatments that
specifically target EBV-infected cells are desirable. The EBVantigen EBNA3C regulates cell cycle by targeting critical cellular complexes such as
cyclin A/cdk2, SCFSkp2, and Rb. Here, we use a 20-amino-acid EBNA3C-derived peptide, fused to an HIV TAT tag for efficient delivery, to
disrupt cell cycle regulation by EBNA3C. The peptide inhibited hyperproliferation of EBV-infected B cell lines and reduced in vitro
immortalization of primary B lymphocytes by EBV. Importantly, the peptide inhibited lymphoblastoid outgrowth from the blood of an EBV-
positive transplant patient in vitro.
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understanding the relationship between molecular disruptions and
cancer phenotypes. Indeed, early work with small DNA tumor
viruses demonstrated that these viruses drive cell proliferation by
targeting and disrupting cell cycle gatekeeper and checkpoint
molecules (DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al.,
1989). In the best characterized example, the adenovirus E1A
protein, high-risk papillomavirus E7 proteins, and the SV40 large
T antigen promote DNA replication by inactivating the retino-
blastoma protein (Rb) (DeCaprio et al., 1988; Dyson et al., 1989;
Whyte et al., 1989). The aforementioned viruses are entirely
dependent on the host cell's replication machinery to propagate
their genomes, and, as such, these viruses likely drive cells into S-⁎ Corresponding author. Department of Microbiology, University of Pennsyl-
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doi:10.1016/j.virol.2006.06.034phase to better access this machinery. Importantly, cancer only
arises when this process becomes deregulated.
Similarly, the activation and proliferation of B lymphocytes
are apparently a fundamental part of Epstein–Barr virus (EBV)
biology. The prevailing model suggests that EBV utilizes its
latency proteins to drive B lymphocyte proliferation, inducing a
phenotype that closely mimics antigen-stimulated B lymphocyte
activation and expansion (Thorley-Lawson, 2001; Thorley-
Lawson et al., 1982, 1985). Not surprisingly, EBV has been
linked to numerous human lymphoproliferative disorders,
including infectious mononucleosis, Burkitt's lymphoma,
Hodgkin's disease, and post-transplant lymphoproliferative
disease (PTLD) (Kieff and Rickinson, 2002; Rickinson and
Kieff, 2002). At present, an open and important question is
whether an EBV latency antigen directly targets cell cycle
regulatory proteins at the molecular level, as has been described
for small DNA tumor virus proteins, or whether EBV relies
primarily on transcriptional regulation to modulate the host's
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implicated transcriptional regulation by latency proteins like
EBNA2, EBNA-LP, and LMP1 (Arvanitakis et al., 1995;
Kempkes et al., 1995; Peng and Lundgren, 1992; Sinclair et
al., 1994). However, more recent studies have begun to suggest a
role for EBNA3C in directly binding and regulating critical cell
cycle proteins.
Initially, EBNA3C was shown to regulate Rb-directed
pathways and to drive cells through the G1/S restriction point
(Parker et al., 1996, 2000). More recently, we demonstrated that
EBNA3C targets the SCFSkp2 complex thereby regulating the
activity and stability of cyclin A/cdk2 and Rb complexes
(Knight and Robertson, 2004; Knight et al., 2005a, 2005b). As
an extension of this work, we hypothesized that the disruption of
EBNA3C-targeted cell cycle pathways might be a viable
method for treating EBV-driven cancers. Interestingly, it was
recently shown that small EBV peptides can be delivered into
cells with high efficiency by tagging the peptides with a basic
sequence derived from the HIV transcriptional transactivator
(TAT) protein (Farrell et al., 2004). We therefore generated a
TAT-tagged peptide corresponding to a region of EBNA3CFig. 1. E3C-TATefficiently enters LCLs. (A) Schematic of EBNA3C depicting the 20
TAT and SCR (scrambled) peptides are indicated. Rb, retinoblastoma protein. (A) C
LCLs were treated with 1 μM E3C-TAT peptide for 24 h. Live cells were imaged at 1
SCR peptide for 24 h and imaged at 600× magnification by confocal microscopy.critical for cell cycle regulation. We then assessed how this
peptide affects both the proliferation of established EBV-
infected cell lines and the de novo immortalization of primary B
lymphocytes by EBV.
Results
The EBNA3C protein is necessary for EBV-mediated B
lymphocyte transformation, although its essential contribution
to transformation has remained unresolved (Tomkinson et al.,
1993). Recently we demonstrated that EBNA3C can modulate
cell cycle regulatory complexes including cyclin A/cdk2,
SCFSkp2, and Rb (Knight and Robertson, 2004; Knight et al.,
2005a, 2005b). These regulatory interactions all map to the
amino terminus of EBNA3C, with a 10-amino-acid stretch from
residues 140–149 being absolutely essential for regulation of
SCFSkp2 and Rb (Fig. 1A) (Knight and Robertson, 2004; Knight
et al., 2005a, 2005b). Here, we decided to test whether
disruption of these interactions, and presumably EBNA3C-
driven cell cycle regulation, would impair EBV-mediated B
lymphocyte proliferation and transformation.-amino-acid region chosen for peptide construction. Complete sequences of E3C-
yclin A. SCF, Skp1/Cullin1/F-box protein. Jκ, RBP-Jκ. LZ, leuzine zipper. (B)
0× magnification. (C) LCLs were treated with 1 μM either E3C-TAT peptide or
Fig. 2. E3C-TAT disrupts the interaction of EBNA3C with Skp2. Skp2 was in
vitro translated and incubated with either GST or GST-EBNA3C amino acids
90–190 (E3C) in binding buffer. Peptide, either 10 or 25 μM as indicated, was
additionally added to some samples. GST fusion proteins were washed
thoroughly with binding buffer and bound proteins were resolved by SDS-
12% PAGE.
209J.S. Knight et al. / Virology 354 (2006) 207–214Short basic stretches of amino acids, sometimes referred to as
protein transduction domains (PTDs), have been shown to
mediate the transport of linked peptides across the plasma
membrane into living cells (Denicourt and Dowdy, 2003; Futaki,
2002; Leifert and Whitton, 2003). Specifically, the PTD of the
HIV transcriptional transactivator (TAT) has been used to deliver
a 10-amino-acid EBNA2 peptide into EBV-infected B lympho-
cytes (Farrell et al., 2004). With the idea that delivery of a short
peptide might interfere with EBNA3C-cell cycle interactions
thereby inhibiting cell proliferation, we designed an EBNA3C-
TAT fusion peptide called E3C-TAT (Fig. 1A). A 20-amino-acid
region of EBNA3C was chosen, amino acids 138–157, which
included the aforementioned regions 140–149, and which was
predicted by several standard secondary structure prediction
protocols to form an alpha helix. An FITC tag was added to the
amino terminus to enable the monitoring of peptide delivery, and
a scrambled peptide was also designed (SCR) (Fig. 1A).
EBNA3C-TAT peptides enter cells and localize to both the
cytoplasm and nucleus
Previously an EBNA2-TAT peptide was shown to enter cells
with a half-maximal uptake of approximately 15 min and a half
life of 24 h for the intracellular peptide (Farrell et al., 2004). The
kinetics for our two peptides, E3C-TAT and SCR, were similar
(data not shown). A representative image is shown in Fig. 1B,
demonstrating peptide in greater than 50% of cells at 24 h when
LCLs were treated with 1 μM E3C-TAT. Essentially identical
results were obtained for the SCR peptide (data not shown).
Further, confocal imaging demonstrated that both peptides were
distributed throughout the cytoplasm and nucleus of treated
cells (Fig. 1C).
The E3C-TAT peptide disrupts EBNA3C/Skp2 complexes in
vitro
Previously, we demonstrated that the amino terminus of
EBNA3C binds the SCFSkp2 complex and utilizes this complex
to regulate Rb stability (Knight et al., 2005a, 2005b). To
confirm that the 20-amino-acid peptide derived from EBNA3C
indeed competes with full-length EBNA3C for binding to
relevant cell cycle molecules, Skp2 was in vitro translated and
incubated with a GST-EBNA3C fusion in the presence of
increasing concentrations of either E3C-TAT peptide or SCR
peptide (Fig. 2). Indeed, E3C-TAT significantly disrupted Skp2
binding to GST-EBNA3C when compared to SCR control
(Fig. 2). Quantitative analysis of the data indicated that 10 μM
E3C-TAT peptide disrupted 80% of Skp2 binding, compared to
only 40% with 10 μM SCR peptide. However, it should be
noted that at higher concentrations of peptide (i.e., 25 μM),
nonspecific competition with the SCR peptide was observed
(Fig. 2).
The E3C-TAT peptide inhibits LCL growth
We predicted that the E3C-TAT peptide would disrupt
necessary EBNA3C interactions and inhibit LCL growth whenintroduced into cells. To test this, we monitored LCL growth
over a 96-h period in the presence of varying concentrations of
peptide. In the presence of 10% bovine growth serum, 5 and
20 μM E3C-TAT inhibited LCL growth in a dose-responsive
fashion (Fig. 3A, left panel). Under conditions of 0.5% serum,
the peptide effect was even more potent with 1 μM E3C-TAT
significantly inhibiting growth at 96 h (Fig. 3A, right panel). To
confirm the specificity of this effect, the SCR peptide was
introduced into two independently prepared LCLs alongside
E3C-TAT, both at 20 μM levels. Again 20 μM E3C-TAT
significantly inhibited LCL growth while 20 μM SCR was
indistinguishable from the no-peptide control (Fig. 3B).
In addition to monitoring LCL proliferation with the
aforementioned growth curve assay, we also measured prolifera-
tion using PKH26, a membrane-staining dye. As cells divide, the
dye is diluted in the plasma membrane resulting in reduced
fluorescence intensity which can be monitored by FACS. Two
independently prepared LCLs were stained with PKH26 and
then maintained in dye-free medium for 72 h. The medium also
contained 10% serum and either E3C-TAT peptide or SCR
control as indicated (Fig. 3C). In LCLs treated with no-peptide or
SCR control, approximately 80% of cells demonstrated reduced
fluorescence intensity and were consequently judged to have
proliferated over the 72-h course of the assay (Fig. 3C). In
contrast, only 40% of E3C-TAT-treated cells showed reduced
fluorescence intensity (Fig. 3C). These PKH26 data are
consistent with the above growth curves demonstrating
decreased LCL proliferation in the presence of the E3C-TAT
peptide.
The E3C-TAT peptide specifically inhibits EBV-infected cells
and EBV-mediated transformation
We next asked whether other B cell lines not infected with
EBV would be similarly inhibited by the E3C-TAT peptide. To
this end, BJAB, DG75, and Loukes were compared alongside an
LCL in a 96-h growth curve experiment. While the LCL again
showed significant growth inhibition in the presence of 20 μM
Fig. 3. E3C-TAT inhibits LCL proliferation. (A) 50,000 LCL cells were seeded into 96-well plates with either 10% or 0.5% bovine growth serum. Cultures were treated
with increasing concentrations of E3C-TAT as indicated. Total cells were counted at 0, 48, and 96 h. (B) 50,000 LCL cells (from two independently established LCLs)
were seeded into 96-well plates with 10% bovine growth serum. Cultures were treated with either E3C-TAT or SCR peptide at a concentration of 20 μM. Total cells
were counted at 0, 48, and 96 h. (C) 500,000 LCL cells (from two independently established LCLs) were stained with PKH26 and seeded into 6-well plates with 10%
bovine growth serum. Cultures were treated with either E3C-TAT or SCR peptide at a concentration of 20 μM. Cells were assayed for extent of proliferation at 72 h.
Quantification of the cells with reduced fluorescence compared to the control is represented.
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TAT were statistically indistinguishable from no-peptide con-
trols (Fig. 4A).
To further explore the EBV dependence of E3C-TAT
inhibition, we asked whether E3C-TAT peptide could inhibit
the transformation of primary B cells by EBV in vitro. Primary
B lymphocytes were prepared from donor blood as described in
Methods (Robertson and Kieff, 1995). Lymphocytes were
mixed with viral supernatant and seeded into 96-well plates. 24
wells were treated with no-peptide, 24 with 20 μM E3C-TAT
peptide, and 24 with 20 μM SCR peptide. Wells were fed every
3 days with fresh medium supplemented with 20 μM peptide.
At 6 weeks, wells were scored for obvious LCL outgrowth by
blinded observers. For the no-peptide control and the SCR-
treated cells, 10 and 11 wells or close to 50% of the wells,
respectively, showed signs of obvious LCL-like outgrowth with
multiple robust foci in each of the wells (Fig. 4B). In contrast,
for E3C-TAT-treated cells only 4 wells showed LCL-like
outgrowth, with fewer foci that did not continue outgrowth over
2–3 months (Fig. 4B).The E3C-TAT peptide inhibits the outgrowth of EBV-positive
lymphoma cells isolated from a PTLD patient
The patient described in Fig. 5 has a history of kidney
transplant for polycystic kidney disease. She developed a B cell,
EBV-positive PTLD 2.5 years ago. At that time, she was treated
with reduction in immunosuppression and rituximab (trade
name Rituxan, an anti-CD20 monoclonal antibody) and had a
complete response. One year later, she developed a new
adenopathy and her EBV PCR (which had been negative for a
year) was again positive. Two preliminary needle biopsies
showed T cells only (no evidence of her old PTLD). However,
she finally had an open biopsy which showed EBV-positive
Hodgkin's disease.
As this patient was in an immunosuppressed state and had a
clear EBV-driven proliferative process, we decided to test
whether the E3C-TAT peptide would prevent spontaneous
EBV-mediated lymphocyte outgrowth from this patient. Total
PBMCs were isolated from patient blood as described in
Methods and seeded into 24-well plates in the presence of either
Fig. 4. E3C-TAT specifically inhibits EBV-immortalized cells. (A) 50,000 cells were seeded into 96-well plates with 10% bovine growth serum. Cultures were treated
with either E3C-TAT or SCR peptide at a concentration of 20 μM. Total cells were counted at 0, 48, and 96 h. (B) Primary B lymphocytes were infected with B95.8
EBV as described in Methods and seeded into a 96-well plate. 24 wells were treated with no-peptide, 24 with 20 μM E3C-TAT peptide, and 24 with 20 μM SCR
peptide. Transformed wells were scored at 6 weeks.
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prepared virus was added and no effort was made to either
extract or inhibit T cells as in the aforementioned transformation
experiments. At 4 weeks, wells were scored for obvious LCL-
like outgrowth by blinded observers.
E3C-TAT significantly inhibited LCL-like outgrowth (Fig.
5A). While 18 and 19 out of 24 wells were scored positive for
no-peptide control and SCR, respectively, only 6 wells were
scored positive for the E3C-TATsample after 4 weeks (Fig. 5A).
Representative LCL-like outgrowths from SCR-treated cells are
shown in Fig. 5B. FACS analysis confirmed that these cells are
CD19-positive (Fig. 5C), and, importantly, three independent
patient-derived LCLs tested by Western blotting were
EBNA3C-positive, confirming the presence of EBV in the
proliferating lymphoblastoid cell lines (Fig. 5D).
Discussion
It is now widely recognized that EBV plays a causative role
in lymproliferative disease of patients receiving sustained
immunosuppression (Nalesnik, 1998). Post-transplant lympho-
proliferative disease (PTLD) is seen in 1% to 2% of renal and
liver transplant patients (Rickinson and Kieff, 2002). Theincidence is even higher in heart and lung transplant recipients
(3% to 8%) where T cell suppression is more dramatic
(Rickinson and Kieff, 2002). The EBV dependence of these
tumors is underscored by immunostaining which invariably
demonstrates lesions with EBNA1, EBNA2, and LMP1-
positive cells, consistent with the formation of LCL-like
outgrowths in the absence of cytotoxic T lymphocyte
surveillance (Liebowitz, 1998; Thomas et al., 1990; Young et
al., 1989). Patients who develop PTLD are generally managed
by reducing the doses of immunosuppressive drugs which will
result in regression of PTLD in approximately half of patients.
Unfortunately, the potential for allograft rejection prohibits this
approach in many patients. An alternative treatment is the CD20
monoclonal antibody rituximab which can be employed alone
or in combination with chemotherapy. Rituximab has variable
effectiveness in patients with follicular B cell non-Hodgkin
lymphoma (Macsween and Crawford, 2003).
EBNA3C is essential for EBV-mediated B lymphocyte
transformation, and presumably proliferation (Tomkinson et al.,
1993). While there is no consensus as to the mechanism by
which EBNA3C contributes to transformation, recent evidence
has clearly implicated EBNA3C in regulation of the cell cycle.
EBNA3C promotes the G1/S transition and targets the SCFSkp2
Fig. 5. E3C-TAT inhibits B lymphocyte outgrowth in an EBV-positive cancer patient. (A) PBMCs were isolated from an EBV-positive, immunosuppressed patient and
seeded into a 96-well plate as described in Methods. 24 wells were treated with no-peptide, 24 with 20 μM E3C-TAT peptide, and 24 with 20 μM SCR peptide.
Transformed wells were scored at 4 weeks. (B) Representative LCL-like outgrowths from SCR peptide-treated wells. (C) LCL-like outgrowths from SCR peptide-
treated wells were stained with either CD19 monoclonal or isotype-control antibody and assayed for fluorescence intensity by FACS. (D) Three independent LCL-like
outgrowths from SCR peptide-treated wells were lysed in SDS-loading buffer (approximately 1 million cells) and resolved by SDS-8% PAGE. Western blotting was
with either EBNA3C monoclonal or actin control antibody. BJAB cells were used as an EBV-negative control. P-LCL, patient-LCL.
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Robertson, 2004; Knight et al., 2005a, 2005b; Parker et al.,
1996, 2000). In this study, we tested whether a small EBNA3C
peptide, with the potential to block the interaction between full-
length EBNA3C and cell cycle regulators, might limit LCL
proliferation and abrogate the transformation of B lymphocytes
by EBV.
For this study, amino acids 138–157 of EBNA3C were
chosen; these include the critical regions 140–149 and are
predicted by several standard secondary structure prediction
protocols to form an alpha helix. These amino acids were fused
to a carboxy-terminal HIV TATwhich had previously been used
to deliver a smaller EBNA2-derived peptide into LCLs (Farrell
et al., 2004). Indeed, the EBNA3C peptide E3C-TAT was
efficiently delivered into cells and, importantly, specifically
inhibited the proliferation of previously established EBV-
infected cell lines. This was in contrast to control experiments
with a scrambled version of the E3C-TAT peptide which
showed no inhibition of proliferation. In another important
control, the E3C-TAT peptide did not inhibit the proliferation of
lymphocyte cell lines which were not infected with EBV. These
data were made more relevant by the ability of the peptide to
inhibit the efficiency of viral transformation of purified primary
B lymphocytes. Finally, the peptide also blocked the sponta-
neous emergence and outgrowth of EBV-transformed cells
when PBMCs were isolated from the blood of an EBV-positive,
immunosuppresed, kidney transplant recipient.
Certainly, further studies are needed to better understand
which of the functions of EBNA3C is specifically disrupted by
the devised peptide. Also, given the known toxicity of the TATpeptide, additional mechanisms may be desirable for the
delivery of EBNA3C inhibitory molecules into cells, including
the identification of small molecule inhibitors that are capable
of specifically inhibiting the aforementioned interactions.
Nevertheless, we find the experiments presented here to be
particularly promising as they relate to the potential role of
EBNA3C-targeting therapeutics in the treatment of EBNA3C-
positive B cell cancers.Methods
Peptide synthesis
Peptides were purchased from Alpha Diagnostic Interna-
tional (San Antonio, Texas). E3C-TAT had a sequence of
Fitc-TQHILCFVMAARQRLQDIRRYGRKKRRQRRR with
an average mass of 4356 daltons. SCR had a sequence of
Fitc-IQRTCQRQAIDLRHVRAMFLYGRKKRRQRRR. Pur-
ity of the peptide preparations was confirmed by HPLC and
peptide identity was confirmed by MS. The 11-amino-acid
HIV TAT tag has been previously described (Farrell et al.,
2004).
GST pull-down assays
GST fusion proteins were purified from bulk E. coli cul-
tures following induction with IPTG as described previously
(Knight et al., 2005b). For in vitro binding experiments, GST
fusion proteins were incubated with 35S-labeled, in vitro
213J.S. Knight et al. / Virology 354 (2006) 207–214translated protein in binding buffer (1× PBS, 0.1% NP40,
0.5 mM DTT, 10% glycerol, supplemented with protease
inhibitors). In vitro translation was with the TNT® T7 Quick
Coupled Transcription/Translation System (Promega Corpora-
tion, Madison, WI).
Growth assays
For growth curves, 50,000 cells were seeded into 100 μl
RPMI 1640 (Invitrogen Corporation, Carlsbad, California).
RPMI was supplemented with the indicated concentrations of
bovine growth serum and either E3C-TAT or SCR peptide.
Cultures were fed every 24 h with 100 μl fresh medium
supplemented with peptide. Total cells were counted with a
hemocytometer at 48 and 96 h.
The optimal concentration of PKH26 (Sigma, St. Louis,
Missouri) for staining and viability of LCLs was determined
to be 4 μM. Staining of cells was per the manufacturer's
recommendation. Briefly, 5×106 cells were pelleted, washed
with medium without serum, and resuspended in 0.5 ml of
diluent, ensuring a single cell suspension by pipetting gently.
Equal volume of PKH26 (8 μM) was added to the single
cell suspension. The cells were incubated at room tempera-
ture for 5 min and the reaction was stopped by adding 1 ml
of ice-cold bovine growth serum. The cells were washed 3
times with ice cold complete medium, to get rid of any free
dye. Immediately following staining with PKH26, staining
was analyzed using a FACScan flow cytometer (BD
Biosciences, San Jose, California). The remaining cells
were divided into samples of 500,000 cells and seeded
into 1 ml RPMI 1640. Media were supplemented with 10%
bovine growth serum and either no-peptide (control) or one
of E3C-TAT or SCR peptides. Cultures were fed every 24 h
with 1 ml fresh medium supplemented with peptide. The
samples were assayed 72 h post-seeding using a FACScan
flow cytometer.
B cell transformation assays
B95.8 virus was prepared from fresh LCLs by seeding 10
million cells into 10 ml RPMI plus 10% bovine growth serum.
Lytic replication was induced by treating cultures with TPA and
butyrate for 6 days. Culture supernatant was harvested and
mixed with clarified cell extracts prepared by freeze/thaw of the
cell pellet. The pooled viral supernatant was passed through a
0.45-μm filter.
Primary B lymphocytes were prepared from donor blood.
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll gradient, and T cells were removed by rosetting with sheep
red blood cells according to standard protocol (Robertson and
Kieff, 1995). Primary B lymphocytes were mixed with viral
supernatant and seeded into 96-well plates with 100,000 cells,
50 μl viral supernatant, and 20 μM peptide per well. Wells were
fed every three days with 50 μl fresh RPMI plus 10% bovine
growth serum, supplemented with 20 μM peptide. At 6 weeks,
wells were scored for obvious LCL outgrowth by blinded
observers.Patient samples
Total PBMCs were isolated from patient blood by Ficoll
gradient and seeded into 96-well plates with 50,000 PBMCs,
50 μl RPMI plus 10% bovine growth serum, and 20 μM peptide
per well. Wells were fed every 3 days with 50 μl fresh RPMI
plus 10% bovine growth serum, supplemented with 20 μM
peptide. At 4 weeks, wells were scored for obvious LCL
outgrowth.
Flow cytometry
2×105 cells were blocked with Fc block (BD Biosciences,
San Jose, California) for 15 min and then stained with
Allophycocyanin (APC)-anti-human CD19 (1:200 dilution,
BD Biosciences) and appropriate isotype control antibody
(1:200 dilution, BD Biosciences) for 30 min at 4 °C. Cells were
collected, washed and acquired with a FACSCalibur flow
cytometer (BD Biosciences) and data were analyzed with
FlowJo software (Tree Star, Inc., Ashland, Oregon).
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